Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan;9(1):3.
doi: 10.21037/atm-20-7474.

The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?

Michael Lock  1 , Brandon M Meyers  2 , Amol Mujoomdar  1
Affiliations
Editorial

The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard?

Michael Lock et al. Ann Transl Med. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-7474). Dr. ML reports personal fees from Ferring, outside the submitted work; and Have received consulting fees from Abbvie, Sanofi, Bayer, and AstraZeneca in the past 10 years. Dr. ML reports personal fees from Ferring, outside the submitted work; and Have received consulting fees from Abbvie, Sanofi, Bayer, and AstraZeneca in the past 10 years. Dr. BMM reports personal fees from Amgen, grants and personal fees from Astra-Zeneca, personal fees from Bayer, personal fees from BMS, grants and personal fees from Eisai, personal fees from Ipsen, grants and personal fees from Merck, personal fees from Roche, personal fees from Sanofi Genzyme, personal fees from Taiho, grants from Sillajen, grants from H3/Eisai, grants from Galera, grants from GSK, grants from Exelixis, outside the submitted work; and Expert testimony for Eisai and Roche. Dr. AM reports personal fees from Boston Scientific, personal fees from Terumo, personal fees from Teleflex, personal fees from Medtronic, outside the submitted work.

Comment on

References

    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed
    1. Liu L, Zhang Q, Geng J, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. 10.21037/atm.2020.03.71 - DOI - PMC - PubMed
    1. Chen L, Ma X, Liu X, et al. Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis. J BUON 2017;22:1525-32. - PubMed
    1. Zhang L, Hu P, Chen X, et al. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 2014;9:e100305. 10.1371/journal.pone.0100305 - DOI - PMC - PubMed

LinkOut - more resources